CCL20/MIP-3 alpha Antibody (4N8C7)

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-27143

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
NBP2-27143
NBP2-27143SS
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Species Reactivity

Mouse

Applications

Western Blot

Label

Unconjugated

Antibody Source

Monoclonal Rat IgG2a Kappa Clone # 4N8C7

Concentration

1.0 mg/ml

View all CCL20/MIP-3 alpha Antibodies »

Product Specifications

Immunogen

Full length recombinant mouse CCL20 (MIP-3a) was used as immunogen for the antibody. full length protein

Reactivity Notes

This monoclonal antibody is specific to mouse CCL20, it will not cross-react with human CCL20.

Clonality

Monoclonal

Host

Rat

Isotype

IgG2a Kappa

Scientific Data Images for CCL20/MIP-3 alpha Antibody (4N8C7)

Western Blot: CCL20/MIP-3 alpha Antibody (4N8C7) [NBP2-27143]

Western Blot: CCL20/MIP-3 alpha Antibody (4N8C7) [NBP2-27143]

Western Blot: CCL20/MIP-3 alpha Antibody (4N8C7) [NBP2-27143] - Analysis of 1) mouse recombinant CCL20 and 2) human recombinant CCL20 using antibody at 0.1 ug/ml.

Applications for CCL20/MIP-3 alpha Antibody (4N8C7)

Application
Recommended Usage

Western Blot

0.1-2ug/ml

Formulation, Preparation, and Storage

Purification

Protein G purified

Formulation

0.2 ml PBS and 0.05% BSA

Preservative

0.05% Sodium Azide

Concentration

1.0 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: CCL20/MIP-3 alpha

CCL20 (MIP-3a) is a small cytokine of the CC chemokine family. It acts as a chemotactic factor that attracts lymphocytes and, slightly, neutrophils, but not monocytes. It is implicated in the formation and function of mucosal lymphoid tissues via chemoattraction of lymphocytes and dendritic cells towards the epithelial cells surrounding these tissues (Zhong W et al, 2010). It is expressed constitutively by keratinocytes in epidermal layers of the skin, intestinal mucosa, epithelial crypts of tonsils, and the epithelium of Payer's patches in the intestine. CCL20 triggers an adaptive immune response primarily by attracting immature dendritic cells expressing CCR6 on their surfaces to the site of inflammation, and allows the dendritic cell to take up a foreign antigen and to mature. After binding, CCR6 expression is down-regulated, causing the dendritic cell to migrate to the lymph nodes, where it binds via CCR7 and presents the antigen to CD8 T cells. Thus it forms a bridge between innate and adaptive immune response (Hoover DM et al, 2002). CCL20 plays immense role in various cancer entities, such as leukaemia, lymphoma, melanoma, hepatocellular carcinoma, prostate cancer, colorectal adenocarcinoma and lung and oral squamous cell carcinoma (He S et al, 2010). CCL20 along with its corresponding receptor CCR6, is significantly up-regulated in patients with pancreatic cancer. But inhibition of CCR6 signaling or neutralization of CCL20 or inhibition of its production and activity may be useful in preventing further progression of the disease and may be a future basic treatment strategy in the management of pancreatic cancer (Rubie C et al, 2010).

Alternate Names

exodus-1, LARC, MIP-3 alpha, MIP3 alpha

Gene Symbol

CCL20

UniProt

O89093

Additional CCL20/MIP-3 alpha Products

Product Documents for CCL20/MIP-3 alpha Antibody (4N8C7)

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for CCL20/MIP-3 alpha Antibody (4N8C7)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.